| Management target | EBITDA Margin 20.0% FY27 |
|---|
| Revenue growth | ₹7,404 Cr, 4% sequential growth led by India quarterly record. |
|---|---|
| Margins | EBITDA margin improved 200 bps QoQ to 18.7% via product mix. |
| Demand visibility | Strong for chronic therapies in India and respiratory assets in US. |
| Management confidence | High on India/US pipeline; cautious on USFDA site remediation timelines. |
Growth
Revenue grew 4% QoQ to ₹7,404 Cr; India branded business outperformed market at 15%.
Outlook
Management maintains FY27 EBITDA margin guidance of 18.5% to 20%.
Risks
Lanreotide supply de-risking remains delayed; Pithampur facility under ongoing USFDA regulatory scrutiny.
Last quarter's promises, checked
Delivered
- Guided Advair approval 'any time' → generic Advair launched (= BEAT)
Partly delivered
- Guided FY27 EBITDA margin 18.5-20% → Q2 18.7%, in range, FY not closed (= PARTIAL)
- Guided $1B US exit run-rate by end-FY27 → target reaffirmed, no Q2 US revenue disclosed (= PARTIAL)
- Guided 4 significant US launches by FY-end → 1 of 4 (Advair) launched, 3 pending (= PARTIAL)
Missed
- Guided R&D 'slightly increased' from 6.8% of revenue → 5.7% (= MISS)
Earnings Call Transcript filed with NSE, NSE: CIPLA. Summary written with AI assistance from the document.
Cipla Ltd: key numbers
- Share price
- ₹1,365.60
- Market cap
- ₹1,10,323 Cr
- Revenue (annual)
- ₹28,163 Cr
- Net profit (annual)
- ₹3,879 Cr
- P/E (TTM)
- 38.1×Sector 46.5×
- Promoter holding
- 29.21%+0.00% QoQ
- FII holding
- 20.24%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cipla Ltd
All →Cipla Employee Stock Options
Cipla granted 8,679 stock options and 27,140 ESARs to employees under its 2013 and 2021 schemes. Exercise price is INR 2 per option with graded vesting.
Cipla Management Change
Cipla's Board appointed Ms. Rashmi Joshi as additional Independent Director for 5 years. This strengthens the board's governance and financial oversight capabilities.
Cipla Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue INR 7,404 Cr (-2.4% YoY), EBITDA INR 1,388 Cr (18.7% margin), PAT INR 878 Cr (11.9%). Record quarterly India revenue; licensing deals in oncology biosimilars and ADCs.
Cipla Results Update
Cipla reported Q2FY27 consolidated revenue of ₹7,404 Cr and PAT of ₹878 Cr. EBITDA margin expanded 200 bps QoQ to 18.7%, with One-India growing 12% YoY.
Cipla Q2 FY27 Results: Net Profit ₹851.5 Cr, Down 37.1% YoY
Cipla Ltd reported revenue from operations of ₹7,404 Cr (-2.4% YoY) and net profit of ₹851.5 Cr (-37.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹851.5 Cr · -37.1% YoY
Cipla Business Update
Cipla's subsidiary InvaGen received zero Form 483 observations in a routine USFDA cGMP inspection. The clean outcome confirms compliance at its US manufacturing facility.